Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Jul
26
Today In Oncology
Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication
Paraneoplastic Neurological Syndromes Associated With Improved Survival in SCLC
POLARGO Trial Shows Survival Benefit With Polatuzumab Vedotin–Based Regimen in Relapsed or Refractory DLBCL
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo